Preclinical differences of intravascular aav9 delivery to neurons and glia

A comparative study of adult mice and nonhuman primates

Steven J. Gray, Valerie Matagne, Lavanya Bachaboina, Swati Yadav, Sergio R. Ojeda, R. Jude Samulski

Research output: Contribution to journalArticle

228 Citations (Scopus)

Abstract

Other labs have previously reported the ability of adeno-associated virus serotype 9 (AAV9) to cross the blood-brain barrier (BBB). In this report, we carefully characterized variables that might affect AAV9's efficiency for central nervous system (CNS) transduction in adult mice, including dose, vehicle composition, mannitol coadministration, and use of single-stranded versus self-complementary AAV. We report that AAV9 is able to transduce approximately twice as many neurons as astrocytes across the entire extent of the adult rodent CNS at doses of 1.25 × 1012, 1 × 1013, and 8 × 1013 vg/kg. Vehicle composition or mannitol coadministration had only modest effects on CNS transduction, suggesting AAV9 crosses the BBB by an active transport mechanism. Self-complementary vectors were greater than tenfold more efficient than single-stranded vectors. When this approach was applied to juvenile nonhuman primates (NHPs) at the middle dose (9-9.5 × 1012 vg/kg) tested in mice, a reduction in peripheral organ and brain transduction was observed compared to mice, along with a clear shift toward mostly glial transduction. Moreover, the presence of low levels of pre-existing neutralizing antibodies (NAbs) mostly occluded CNS and peripheral transduction using this delivery approach. Our results indicate that high peripheral tropism, limited neuronal transduction in NHPs, and pre-existing NAbs represent significant barriers to human translation of intravascular AAV9 delivery.

Original languageEnglish (US)
Pages (from-to)1058-1069
Number of pages12
JournalMolecular Therapy
Volume19
Issue number6
DOIs
StatePublished - Jun 1 2011

Fingerprint

Dependovirus
Neuroglia
Primates
Central Nervous System
Neurons
Mannitol
Neutralizing Antibodies
Blood-Brain Barrier
Tropism
Active Biological Transport
Astrocytes
Rodentia
Serogroup
Brain

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Preclinical differences of intravascular aav9 delivery to neurons and glia : A comparative study of adult mice and nonhuman primates. / Gray, Steven J.; Matagne, Valerie; Bachaboina, Lavanya; Yadav, Swati; Ojeda, Sergio R.; Samulski, R. Jude.

In: Molecular Therapy, Vol. 19, No. 6, 01.06.2011, p. 1058-1069.

Research output: Contribution to journalArticle

Gray, Steven J. ; Matagne, Valerie ; Bachaboina, Lavanya ; Yadav, Swati ; Ojeda, Sergio R. ; Samulski, R. Jude. / Preclinical differences of intravascular aav9 delivery to neurons and glia : A comparative study of adult mice and nonhuman primates. In: Molecular Therapy. 2011 ; Vol. 19, No. 6. pp. 1058-1069.
@article{bc2a92aba7034f3ab92203f56ba1fb03,
title = "Preclinical differences of intravascular aav9 delivery to neurons and glia: A comparative study of adult mice and nonhuman primates",
abstract = "Other labs have previously reported the ability of adeno-associated virus serotype 9 (AAV9) to cross the blood-brain barrier (BBB). In this report, we carefully characterized variables that might affect AAV9's efficiency for central nervous system (CNS) transduction in adult mice, including dose, vehicle composition, mannitol coadministration, and use of single-stranded versus self-complementary AAV. We report that AAV9 is able to transduce approximately twice as many neurons as astrocytes across the entire extent of the adult rodent CNS at doses of 1.25 × 1012, 1 × 1013, and 8 × 1013 vg/kg. Vehicle composition or mannitol coadministration had only modest effects on CNS transduction, suggesting AAV9 crosses the BBB by an active transport mechanism. Self-complementary vectors were greater than tenfold more efficient than single-stranded vectors. When this approach was applied to juvenile nonhuman primates (NHPs) at the middle dose (9-9.5 × 1012 vg/kg) tested in mice, a reduction in peripheral organ and brain transduction was observed compared to mice, along with a clear shift toward mostly glial transduction. Moreover, the presence of low levels of pre-existing neutralizing antibodies (NAbs) mostly occluded CNS and peripheral transduction using this delivery approach. Our results indicate that high peripheral tropism, limited neuronal transduction in NHPs, and pre-existing NAbs represent significant barriers to human translation of intravascular AAV9 delivery.",
author = "Gray, {Steven J.} and Valerie Matagne and Lavanya Bachaboina and Swati Yadav and Ojeda, {Sergio R.} and Samulski, {R. Jude}",
year = "2011",
month = "6",
day = "1",
doi = "10.1038/mt.2011.72",
language = "English (US)",
volume = "19",
pages = "1058--1069",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Preclinical differences of intravascular aav9 delivery to neurons and glia

T2 - A comparative study of adult mice and nonhuman primates

AU - Gray, Steven J.

AU - Matagne, Valerie

AU - Bachaboina, Lavanya

AU - Yadav, Swati

AU - Ojeda, Sergio R.

AU - Samulski, R. Jude

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Other labs have previously reported the ability of adeno-associated virus serotype 9 (AAV9) to cross the blood-brain barrier (BBB). In this report, we carefully characterized variables that might affect AAV9's efficiency for central nervous system (CNS) transduction in adult mice, including dose, vehicle composition, mannitol coadministration, and use of single-stranded versus self-complementary AAV. We report that AAV9 is able to transduce approximately twice as many neurons as astrocytes across the entire extent of the adult rodent CNS at doses of 1.25 × 1012, 1 × 1013, and 8 × 1013 vg/kg. Vehicle composition or mannitol coadministration had only modest effects on CNS transduction, suggesting AAV9 crosses the BBB by an active transport mechanism. Self-complementary vectors were greater than tenfold more efficient than single-stranded vectors. When this approach was applied to juvenile nonhuman primates (NHPs) at the middle dose (9-9.5 × 1012 vg/kg) tested in mice, a reduction in peripheral organ and brain transduction was observed compared to mice, along with a clear shift toward mostly glial transduction. Moreover, the presence of low levels of pre-existing neutralizing antibodies (NAbs) mostly occluded CNS and peripheral transduction using this delivery approach. Our results indicate that high peripheral tropism, limited neuronal transduction in NHPs, and pre-existing NAbs represent significant barriers to human translation of intravascular AAV9 delivery.

AB - Other labs have previously reported the ability of adeno-associated virus serotype 9 (AAV9) to cross the blood-brain barrier (BBB). In this report, we carefully characterized variables that might affect AAV9's efficiency for central nervous system (CNS) transduction in adult mice, including dose, vehicle composition, mannitol coadministration, and use of single-stranded versus self-complementary AAV. We report that AAV9 is able to transduce approximately twice as many neurons as astrocytes across the entire extent of the adult rodent CNS at doses of 1.25 × 1012, 1 × 1013, and 8 × 1013 vg/kg. Vehicle composition or mannitol coadministration had only modest effects on CNS transduction, suggesting AAV9 crosses the BBB by an active transport mechanism. Self-complementary vectors were greater than tenfold more efficient than single-stranded vectors. When this approach was applied to juvenile nonhuman primates (NHPs) at the middle dose (9-9.5 × 1012 vg/kg) tested in mice, a reduction in peripheral organ and brain transduction was observed compared to mice, along with a clear shift toward mostly glial transduction. Moreover, the presence of low levels of pre-existing neutralizing antibodies (NAbs) mostly occluded CNS and peripheral transduction using this delivery approach. Our results indicate that high peripheral tropism, limited neuronal transduction in NHPs, and pre-existing NAbs represent significant barriers to human translation of intravascular AAV9 delivery.

UR - http://www.scopus.com/inward/record.url?scp=79957888016&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957888016&partnerID=8YFLogxK

U2 - 10.1038/mt.2011.72

DO - 10.1038/mt.2011.72

M3 - Article

VL - 19

SP - 1058

EP - 1069

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 6

ER -